Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.

Daniel J Olson Zeynep Eroglu Bruce E Brockstein Andrew S PoklepovicMadhuri BajajSunil BabuSigrun HallmeyerMario Velasco Jose Lutzky Emily F HiggsRiyue BaoTimothy Clifford Carll Brian LabadieThomas KrauszYuanyuan ZhaTheodore KarrisonVernon K SondakThomas F GajewskiNikhil I Khushalani Jason John Luke

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

To our knowledge, this is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

Keyphrases

low dose
advanced non small cell lung cancer
healthcare
skin cancer
high dose
open label
basal cell carcinoma